Veryan Medical Revenue and Competitors

Veryan has developed innovative technology to improve the performance of vascular stents by adopting the principle of biomimicry; developing structures that imitate those occurring naturally. Veryan's vascular biomimetic stent technology involves adapting a straight stent design to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. The BioMimics 3D stent belongs to a new generation of self-expanding stent design with advanced biomechanical and flow performance properties, creating the potential to transform the treatment of patients with symptomatic peripheral arterial disease of the lower limbs. This highly differentiated technology has been clinically proven in a multicentre, randomised clinical trial (the Mimics study) in superficial femoral and proximal popliteal (femoropopliteral) arteries of the leg and received CE Mark approval in November 2012. Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.1 Veryan benefits from a highly experienced Board of Directors and the Company's management team has built an outstanding development group, supported by a world class Scientific Advisory Board. The Company's head office is in Horsham, West Sussex, UK, and the research and development facility is in Galway, Ireland. Veryan Medical is a member of the Otsuka Medical Devices Group. Veryan's Quality Management System is certified in compliance with I.S. EN ISO 13485:2012